Carlo R Largiadèr
Comparison of methods for donor-derived cell-free DNA quantification in plasma and urine from solid organ transplant recipients.
Kueng N, Arcioni S, Sandberg F, Kuhn C, Banz V, Largiadèr C, Sidler D, Amstutz U. Comparison of methods for donor-derived cell-free DNA quantification in plasma and urine from solid organ transplant recipients. Front Genet 2023; 14:1089830.
Jan 27, 2023Comparison of methods for donor-derived cell-free DNA quantification in plasma and urine from solid organ transplant recipients.
Jan 27, 2023Front Genet 2023; 14:1089830
Kueng Nicholas, Arcioni Séverine, Sandberg Fanny, Kuhn Christian, Banz Vanessa, Largiadèr Carlo R, Sidler Daniel, Amstutz Ursula
Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP).
Schmulenson E, Bovet C, Theurillat R, Decosterd L, Largiadèr C, Prost J, Csajka C, Bärtschi D, Guckenberger M, von Moos R, Bastian S, Jörger M, Jaehde U. Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP). Br J Clin Pharmacol 2022; 88:5336-5347.
Jul 23, 2022Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP).
Jul 23, 2022Br J Clin Pharmacol 2022; 88:5336-5347
Schmulenson Eduard, Bovet Cédric, Theurillat Regula, Decosterd Laurent Arthur, Largiadèr Carlo R, Prost Jean-Christophe, Csajka Chantal, Bärtschi Daniela, Guckenberger Matthias, von Moos Roger, Bastian Sara, Jörger Markus, Jaehde Ulrich
Clinical Implementation of Pharmacogenetic Testing to Prevent Early-Onset Fluoropyrimidine-Related Toxicity in Cancer Patients in Switzerland.
Begré U, Jörger M, Aebi S, Amstutz U, Largiadèr C. Clinical Implementation of Pharmacogenetic Testing to Prevent Early-Onset Fluoropyrimidine-Related Toxicity in Cancer Patients in Switzerland. Front Pharmacol 2022; 13:885259.
May 18, 2022Clinical Implementation of Pharmacogenetic Testing to Prevent Early-Onset Fluoropyrimidine-Related Toxicity in Cancer Patients in Switzerland.
May 18, 2022Front Pharmacol 2022; 13:885259
Begré Ursina B M, Jörger Markus, Aebi Stefan, Amstutz Ursula, Largiadèr Carlo R
The Swiss Primary Hypersomnolence and Narcolepsy Cohort study (SPHYNCS): Study protocol for a prospective, multicentre cohort observational study.
Dietmann A, Wenz E, van der Meer J, Ringli M, Warncke J, Edwards E, Schmidt M, Bernasconi C, Nirkko A, Strub M, Miano S, Manconi M, Acker J, Von Manitius S, Baumann C, Valko P, Yilmaz B, Brunner A, Tzovara A, Zhang Z, Largiadèr C, Tafti M, Latorre D, Sallusto F, Khatami R, Bassetti C. The Swiss Primary Hypersomnolence and Narcolepsy Cohort study (SPHYNCS): Study protocol for a prospective, multicentre cohort observational study. J Sleep Res 2021; 30:e13296.
Apr 4, 2021The Swiss Primary Hypersomnolence and Narcolepsy Cohort study (SPHYNCS): Study protocol for a prospective, multicentre cohort observational study.
Apr 4, 2021J Sleep Res 2021; 30:e13296
Dietmann Anelia, Wenz Elena, van der Meer Julia, Ringli Maya, Warncke Jan D, Edwards Ellen, Schmidt Markus, Bernasconi Corrado A, Nirkko Arto, Strub Mathias, Miano Silvia, Manconi Mauro, Acker Jens, Von Manitius Sigrid, Baumann Christian R, Valko Philip O, Yilmaz Bahtiyar, Brunner Andreas-David, Tzovara Athina, Zhang Zhongxing, Largiadèr Carlo R, Tafti Mehdi, Latorre Daniela, Sallusto Federica, Khatami Ramin, Bassetti Claudio
A Novel Nomenclature for Repeat Motifs in the Thymidylate Synthase Enhancer Region and Its Relevance for Pharmacogenetic Studies
Schaerer D, Froehlich T, Hamzic S, Offer S, Diasio R, Jörger M, Amstutz U, Largiadèr C. A Novel Nomenclature for Repeat Motifs in the Thymidylate Synthase Enhancer Region and Its Relevance for Pharmacogenetic Studies. J Pers Med 2020; 10
Oct 19, 2020A Novel Nomenclature for Repeat Motifs in the Thymidylate Synthase Enhancer Region and Its Relevance for Pharmacogenetic Studies
Oct 19, 2020J Pers Med 2020; 10
Schaerer Dominic, Froehlich Tanja K, Hamzic Seid, Offer Steven M, Diasio Robert B, Jörger Markus, Amstutz Ursula, Largiadèr Carlo R
Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis
Hamzic S, Amstutz U, López-Fernández L, García-González X, Schellens J, Meulendijks D, Thomlinson I, Palles C, Aebi S, Jörger M, Froehlich T, Kummer D, Largiadèr C. Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis. Pharmacol Res 2019; 152:104594.
Dec 12, 2019Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis
Dec 12, 2019Pharmacol Res 2019; 152:104594
Hamzic Seid, Amstutz Ursula, López-Fernández Luis A, García-González Xandra, Schellens Jan H M, Meulendijks Didier, Thomlinson Ian, Palles Claire, Aebi Stefan, Jörger Markus, Froehlich Tanja K, Kummer Dominic, Largiadèr Carlo R
Dihydropyrimidinase and β-ureidopropionase gene variation and severe fluoropyrimidine-related toxicity.
Kummer D, Froehlich T, Joerger M, Aebi S, Sistonen J, Amstutz U, Largiadèr C. Dihydropyrimidinase and β-ureidopropionase gene variation and severe fluoropyrimidine-related toxicity. Pharmacogenomics 2015; 16:1367-77.
Aug 5, 2015Dihydropyrimidinase and β-ureidopropionase gene variation and severe fluoropyrimidine-related toxicity.
Aug 5, 2015Pharmacogenomics 2015; 16:1367-77
Kummer Dominic, Froehlich Tanja K, Joerger Markus, Aebi Stefan, Sistonen Johanna, Amstutz Ursula, Largiadèr Carlo R
Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy.
Amstutz U, Offer S, Sistonen J, Joerger M, Diasio R, Largiadèr C. Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy. Clin Cancer Res 2015; 21:2038-44.
Feb 5, 2015Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy.
Feb 5, 2015Clin Cancer Res 2015; 21:2038-44
Amstutz Ursula, Offer Steven M, Sistonen Johanna, Joerger Markus, Diasio Robert B, Largiadèr Carlo R
Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity
Froehlich T, Amstutz U, Aebi S, Jörger M, Largiadèr C. Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity. Int J Cancer 2014; 136:730-9.
Jun 27, 2014Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity
Jun 27, 2014Int J Cancer 2014; 136:730-9
Froehlich Tanja K, Amstutz Ursula, Aebi Stefan, Jörger Markus, Largiadèr Carlo R
Comparative evaluation of the My5-FU™ immunoassay and LC-MS/MS in monitoring the 5-fluorouracil plasma levels in cancer patients
Büchel B, Sistonen J, Jörger M, Aebi Y, Schürch S, Largiadèr C. Comparative evaluation of the My5-FU™ immunoassay and LC-MS/MS in monitoring the 5-fluorouracil plasma levels in cancer patients. Clin Chem Lab Med 2013; 51:1681-8.
Aug 1, 2013Comparative evaluation of the My5-FU™ immunoassay and LC-MS/MS in monitoring the 5-fluorouracil plasma levels in cancer patients
Aug 1, 2013Clin Chem Lab Med 2013; 51:1681-8
Büchel Barbara, Sistonen Johanna, Jörger Markus, Aebi Yolanda, Schürch Stefan, Largiadèr Carlo R